OUR team
We are a group of antidisciplinary scientists and builders working at the intersection of engineering and biology.
Abdul Mohammed
Associate Director - Genomic Applications
Akim Lennhoff
Principal Instrumentation Engineer
Alex Gushulak
Mechanical Engineer
.jpg)
Alexandra Franklin
Senior Operations Associate
.jpg)
Allyson Miller
Senior Operations Associate
.jpg)
Angela Fee
Bioengineering Co-op
Ben Fargiano
Mechanical Engineer
.jpg)
Brandon Hao
Electrical Engineering Co-Op
.jpg)
Catherine Griffin
Bioengineering Co-Op
Cédric Viry
Senior Materials/R&D Engineer
Dan Curhan
Mechatronics Engineering Lead
.jpg)
Daniel Giguere
Scientist - Genomic Applications
Devin Junkins
Systems Integration Engineer
.jpg)
Emma Young
Bioengineering Co-op
Febriana Pangestu
Associate Scientist
Gabriella Davis
Research Associate
Grayson Daly
Mechatronics Engineer
.jpg)
Jaiden Cruger
Systems Integration Engineer
James Ferguson
Principal Software Engineer
Keith Farnsworth
Chief Commercial Officer
.jpg)
Kelly Snyder
Senior Electrical Engineer
Liam Masters
Software Engineer
.jpg)
Nic Bryant
Staff Product Manager
.jpg)
Richard Kaufman
Mechanical Engineering Co-Op
Rithika Raj Kumar Pradeep
Research Associate
Udayan Umapathi
Co-founder and CEO
.jpg)
Vidhi Nayyar
Visual and Industrial Design Co-Op
Will Langford
Co-founder and Head of Engineering
Board of directors
We are proud to have the support of industry CEOs who have built large, successful companies providing us strategic advice.
Natan Linder
CEO
Tulip Interfaces
David Singer
Director
Managing Partner, Maverick Ventures
Maxim Lobovsky
CEO
Formlabs
Udayan Umapathi
Co-founder and CEO
Volta Labs
INDIVIDUAL INVESTORS AND ADVISORS
Standing on the shoulders of industry giants.
John Stuelpnagel
Co-founder & Board Member
Illumina, 10X Genomics & Others
Paul McEwan
Co- founder & Board Member
Kapa Biosystems & Others
Preston Estep
Director
Harvard Personal Genome Project
Maryke Appel
Technical Director (former)
Kapa Biosystems & Roche
George Church
Professor
Harvard Medical School
Investors
Backed by investors with long term perspective in genomics
